4
Changes in Ownership
GeneDx Holdings Corp. Filed Acc 0001689575-26-000032
CHIEF EXECUTIVE OFFICER sold 10,501 shares at an average $97.61 ($1,025,013)
- CHIEF EXECUTIVE OFFICER acquired 18,750 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-09-16 | Option exercise | +18,750 | 125,977 | D | ||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-09-16 | Sale | −1,648 | $94.26 | $155,337 | 124,329 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-09-16 | Sale | −148 | $95.41 | $14,120 | 124,181 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-09-16 | Sale | −1,525 | $96.90 | $147,774 | 122,656 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-09-16 | Sale | −4,141 | $98.27 | $406,936 | 118,515 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-09-16 | Sale | −3,039 | $99.00 | $300,846 | 115,476 | D |
| Derivatives | |||||||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-09-16 | Option exercise · Restricted Stock Unit | −18,750 | 37,500 | D | ||
| Open-market sales · 10,501 sh · avg $97.61 · $1,025,013 | |||||||
Loading xslF345X06/form4-09182026_080912.xml…